Amalya Sargsyan: Excitement around osimertinib in the NSCLC community
Amalya Sargsyan, Medical Oncologist at Yeolyan Hematology and Oncology Center, shared a post on LinkedIn:
“Huge excitement around TAGRISSO® (osimertinib) HCP in the NSCLC community, as recent results continue to picture promising outcomes for the EGFRmut population in both adjuvant settings and beyond. While celebrating these truly remarkable advancements, came up with an intriguing abstract about the other side of the story.
Patients’ preferences for adjuvant osimertinib in NSCLC after complete surgical resection: What makes it worth it to patients?
66% of patients look for a ≥12-month OS leap before saying ‘yes’ to adjuvant Osimertinib.
For 66%, a boost in DFS by 6+ months is compelling, but overall interest varies.
Minimal gains (1 month) in DFS or OS don’t convince 60% and 78% of patients.
A 1% increase in 5-year OS persuades patients to accept Osimertinib for three years, despite potential toxicity.
Now, we may wonder: How will patients react to combining chemotherapy with osimertinib? And what thresholds will justify the toxicity associated with chemo?
While the study population might not align perfectly, and I acknowledge the limitations, but the message is there: patients deserve a voice in their treatment choices. Sometimes, our clinical milestones don’t align with patient priorities, reminding us to balance statistical significance with what’s genuinely significant to each patient.”
Source: Amalya Sargsyan/LinkedIn